PharmaCyte Biotech, Inc.(PMCB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PMCB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for PharmaCyte Biotech, Inc. (PMCB), a Healthcare sector company. PMCB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.1m in revenue. Based on the latest XBRL financial filings (Q3 2026), PharmaCyte Biotech, Inc. reports net income of $746.9K, free cash flow of $-786.8K. Top institutional holders of PMCB by reported 13-F value include CITADEL ADVISORS, GEODE CAPITAL MANAGEMENT,, CITADEL ADVISORS, based on the most recent SEC filings. PMCB trades on the Nasdaq exchange and files with the SEC under CIK 1157075. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PMCB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PharmaCyte Biotech, Inc. directly from SEC EDGAR.
Revenue
Q3 2026
$0.00
Net Income
Q3 2026
$746.9K
Free Cash Flow
Q3 2026
$-786.8K
ROIC
Q3 2026
-5.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+810.3% YoYOperating Income
+32.2% YoYEPS (Diluted)
+1550.0% YoYTotal Assets
-24.7% YoYOp. Cash Flow
+21.5% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $30.7M +810.3% | $-4.3M -1.8% | $-4.2M -19.4% | $-3.6M +12.7% | $-4.1M +40.4% | $-6.8M |
| Operating Income | $-4.4M +32.2% | $-6.5M -47.0% | $-4.4M -21.2% | $-3.6M +11.6% | $-4.1M +41.3% | $-7.0M |
| EPS (Diluted) | $3.19 +1550.0% | $-0.22 +18.5% | $-0.27 +25.1% | $-0.36 | — | — |
| Total Assets | $55.2M -24.7% | $73.3M -19.1% | $90.6M +1124.0% | $7.4M +28.0% | $5.8M -9.8% | $6.4M |
| Operating Cash Flow | $-3.0M +21.5% | $-3.8M +7.9% | $-4.1M -23.6% | $-3.3M -15.7% | $-2.9M +43.3% | $-5.1M |
Get alerted when PMCB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PharmaCyte Biotech, Inc. including:
Top Institutional Holders of PMCB
CITADEL ADVISORS LLC
$239.2K359,547 shGEODE CAPITAL MANAGEMENT, LLC
$130.2K195,660 shCITADEL ADVISORS LLC
$106.6K160,200 shRENAISSANCE TECHNOLOGIES LLC
$37.6K56,500 shXTX Topco Ltd
$34.8K52,362 shVANGUARD CAPITAL MANAGEMENT LLC
$34.2K51,467 shNORTHERN TRUST CORP
$23.7K35,601 shSchonfeld Strategic Advisors LLC
$18.0K27,009 shVANGUARD FIDUCIARY TRUST CO
$15.6K23,452 shEQUITEC PROPRIETARY MARKETS, LLC
$14.8K22,227 sh
| Fund | Value | Shares |
|---|---|---|
| CITADEL ADVISORS LLC | $239.2K | 359,547 |
| GEODE CAPITAL MANAGEMENT, LLC | $130.2K | 195,660 |
| CITADEL ADVISORS LLC | $106.6K | 160,200 |
| RENAISSANCE TECHNOLOGIES LLC | $37.6K | 56,500 |
| XTX Topco Ltd | $34.8K | 52,362 |
| VANGUARD CAPITAL MANAGEMENT LLC | $34.2K | 51,467 |
| NORTHERN TRUST CORP | $23.7K | 35,601 |
| Schonfeld Strategic Advisors LLC | $18.0K | 27,009 |
| VANGUARD FIDUCIARY TRUST CO | $15.6K | 23,452 |
| EQUITEC PROPRIETARY MARKETS, LLC | $14.8K | 22,227 |
More Healthcare Companies
View all Healthcare →Put PMCB on your watchlist
Track score changes the day PharmaCyte Biotech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PMCB a good stock to buy?
13F Pro's AI-powered analysis of PharmaCyte Biotech, Inc. (PMCB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PMCB are available on the PMCB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PMCB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PMCB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PharmaCyte Biotech, Inc.'s investment landscape.